TG Therapeutics, Inc. (TGTX)
| Market Cap | 5.11B |
| Revenue (ttm) | 616.29M |
| Net Income (ttm) | 447.18M |
| Shares Out | 147.68M |
| EPS (ttm) | 2.77 |
| PE Ratio | 12.48 |
| Forward PE | 26.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,271,602 |
| Open | 35.61 |
| Previous Close | 35.38 |
| Day's Range | 34.44 - 36.01 |
| 52-Week Range | 25.28 - 46.48 |
| Beta | 1.76 |
| Analysts | Strong Buy |
| Price Target | 49.80 (+44.01%) |
| Earnings Date | May 4, 2026 |
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ... [Read more]
Financial Performance
In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price target is $49.8, which is an increase of 44.01% from the latest price.
News
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLO...
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives Additional funding provides financial flexibility to expan...
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies eval...
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with...
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
TG Therapeutics Earnings Call Transcript: Q4 2025
Delivered $616M global revenue in 2025, driven by 92% year-over-year BRIUMVI growth and strong Q4. Reaffirmed 2026 guidance of $825–$850M U.S. net revenue, with continued share gains, robust pipeline progress, and expanded commercial initiatives.
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS Campaign debuted during Super Bowl LX...
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Com...
TG Therapeutics Stock Climbs After The Bell: Here's Why
TG Therapeutics, Inc. (NASDAQ: TGTX) shares climbed in Tuesday's extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 202...
TG Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Briumvi continues to gain market share in MS, surpassing $1 billion in sales and driving strong revenue growth. Key initiatives for 2026 include expanding the sales force, launching patient awareness campaigns, and advancing pivotal trials for new dosing and subcu formulations. Briumvi's pipeline and patent life support long-term growth.
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 44th An...
TG Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Briumvi is targeting $585 million in revenue this year, with significant growth expected next year. Market share gains are tied to increasing patient awareness, and targeted sales force expansion is underway. Sub-Q and CAR-T programs are progressing, with key data expected in 2024 and 2026.
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th ...
TG Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
Briumvi is gaining first-line IV status due to strong data, convenience, and robust patient support. SUB-Q formulation is expected to nearly double the addressable market, with pivotal trial data anticipated by late 2025 or early 2027. Q4 growth is expected to outpace Q3, and direct-to-consumer efforts will expand in 2026.
TG Therapeutics Earnings Call Transcript: Q3 2025
Q3 saw record BRIUMVI sales, 93% revenue growth year-over-year, and raised 2025 guidance to $585M. Profitability continued for a sixth quarter, with strong patient retention, expanding field force, and pipeline progress supporting long-term growth.
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for th...
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a conso...
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with...
TG Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The company is expanding its market share in the IV MS therapy segment, with strong real-world efficacy and tolerability data. Key pipeline developments include a subcutaneous formulation and a new dosing regimen, with pivotal data expected in 2026–2028. Early-stage programs and ex-US partnerships are progressing, but US sales remain the primary revenue driver.
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), ...
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.